IMEP (chemotherapy)

From Wikipedia, the free encyclopedia

IMEP is a chemotherapy regimen that is effective for nasal NK- / T-cell lymphoma.[1] This chemotherapy regimen was also tested in Hodgkin disease as a part of a multidrug alternating scheme COPP / ABV / IMEP. But in that setting it showed no advantage in efficacy and toxicity compared to the use of ABVD or the alternating COPP / ABVD scheme.[2]

Drug regimen[edit]

Drug Dose Mode Days
(I)fosfamide 1500 mg/m2 with mesna IV infusion Days 1-3
(M)ethotrexate 30 mg/m2 IV bolus Days 3 and 10
(E)toposide 100 mg/m2 IV infusion Days 1-3
(P)rednisone 120 mg PO qd Days 1-5

References[edit]

  1. ^ "IMEP protocol in nasal NK/T-cell lymphoma". Archived from the original on 2014-09-11. Retrieved 2014-09-11.
  2. ^ Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial
Retrieved from "https://en.wikipedia.org/w/index.php?title=IMEP_(chemotherapy)&oldid=1050520164"